Pfizer Inc. (NYSE:PFE) Shares Purchased by Strategic Advisors LLC

Strategic Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 131,266 shares of the biopharmaceutical company’s stock after acquiring an additional 4,473 shares during the quarter. Strategic Advisors LLC’s holdings in Pfizer were worth $3,799,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Wasatch Advisors LP lifted its stake in Pfizer by 21.0% during the fourth quarter. Wasatch Advisors LP now owns 167,300 shares of the biopharmaceutical company’s stock worth $4,817,000 after purchasing an additional 29,000 shares in the last quarter. Icon Wealth Advisors LLC purchased a new position in Pfizer during the 4th quarter valued at about $479,000. Redwood Investment Management LLC grew its position in Pfizer by 1.8% in the 4th quarter. Redwood Investment Management LLC now owns 81,252 shares of the biopharmaceutical company’s stock valued at $2,339,000 after acquiring an additional 1,465 shares in the last quarter. Pinnacle Holdings LLC increased its stake in Pfizer by 24.0% during the fourth quarter. Pinnacle Holdings LLC now owns 6,712 shares of the biopharmaceutical company’s stock worth $193,000 after purchasing an additional 1,300 shares during the period. Finally, New England Asset Management Inc. lifted its position in shares of Pfizer by 1.6% during the fourth quarter. New England Asset Management Inc. now owns 170,098 shares of the biopharmaceutical company’s stock worth $4,897,000 after purchasing an additional 2,743 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research reports. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday. Barclays upped their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Wells Fargo & Company lifted their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Thursday, October 3rd. Finally, UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Stock Performance

NYSE:PFE traded down $0.83 during trading hours on Thursday, reaching $29.36. 20,645,180 shares of the company’s stock were exchanged, compared to its average volume of 37,357,430. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $33.92. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $166.37 billion, a price-to-earnings ratio of -496.00, a P/E/G ratio of 1.23 and a beta of 0.67. The company has a 50-day moving average of $29.09 and a 200 day moving average of $28.36.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.67 earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.72%. Pfizer’s payout ratio is currently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.